drugset / Trial / NCT00606034

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod

NCT00606034 ↗

Phase 4 Completed 21 enrolled Mountain Diabetes and Endocrine Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Patients with Type 2 diabetes and severe insulin resistance with very large insulin requirements who have failed all previous insulin regimens using non-concentrated forms of insulin (U100 insulin formulations) will receive 5X concentrated insulin (U500 regular insulin)infused via insulin pump.

Timeline

Start
2007-12
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject U-500 Insulin Unknown — Subcutaneous